BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
1) Support corporate tax policies which protect US research and manufacturing jobs, including issues related to US corporate tax rate, transfer pricing and patent box.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Medicare/Medicaid MMM
Advocacy to reform IPAB to ensure patient access to medically necessary therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Copyright/Patent/Trademark CPT
Patent Reform -- S. 23 and HR 1249 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, with a specific focus on damages provisions, inequitable conduct, and post-grant/second window. Opposition to inclusion of patent settlements legislation in appropriations bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Health Issues HCR
1) Implementation of biosimilars regulations to support incentives for innovation and second generation therapies. 2) Support for passage of the PDUFA reathorization to increase transparency and efficiency of the drug review process at FDA
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.